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 Abstract 
Objective: A large, pivotal, phase 3 trial in patients with newly diagnosed multiple myeloma (MM) 
demonstrated that denosumab, compared with zoledronic acid, was non-inferior for the prevention 
of skeletal-related events (SREs), extended the observed median progression-free survival (PFS) by 
10.7 months, and showed significantly less renal toxicity. The cost-effectiveness of denosumab 
versus zoledronic acid in MM in the United States of America was assessed from societal and payer 
perspectives. 
 
Methods: The XGEVA® Global Economic Model was developed by integrating data from the phase 3 
trial comparing the efficacy of denosumab with zoledronic acid for the prevention of SREs in MM. 
SRE rates were adjusted to reflect the real-world incidence. The model included utility decrements 
for SREs, administration, serious adverse events (SAEs), and disease progression. Drug, 
administration, SRE management, SAEs, and anti-MM treatment costs were based on data from 
published studies. For the societal perspective, the model additionally included SRE-related direct 
non-medical costs and indirect costs. The net monetary benefit (NMB) was calculated using a 
willingness to pay threshold of US$150,000. One-way deterministic and probabilistic sensitivity 
analyses were conducted. 
 
Results: From a societal perspective, compared with zoledronic acid, the use of denosumab resulted 
in an incremental cost of US$26,329 and an incremental quality-adjusted life-year (QALY) of 0.2439, 
translating into a cost per QALY gained of US$107,939 and a NMB of US$10,259 in favor of 
denosumab. Results were sensitive to SRE rates and PFS parameters. 
 
Limitations: Costs were estimated from multiple sources, which varied by tumor type, patient 
population, country, and other parameters. PFS and overall survival were extrapolated beyond the 
follow-up of the primary analysis using fitted parametric curves. 
 
Conclusion: Denosumab’s efficacy in delaying or preventing SREs, potential to improve PFS, and lack 
of renal toxicity makes it a cost-effective option for the prevention of SREs in MM compared with 
zoledronic acid. 
 
Keywords: Cost-effectiveness; Denosumab, Zoledronic acid; Skeletal-related events; Multiple 
myeloma 
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 Introduction 
Multiple myeloma (MM) is a rare, incurable and aggressive cancer of plasma cell origin that accounts 
for 1.8% of all cancers in the United States of America (USA) and is the second most common 
hematological malignancy1, 2. It is characterized by a chronic pattern of remission and relapse and 
features increased osteoclast activation, resulting from an imbalance between receptor activator of 
nuclear factor kappa B ligand (RANKL) and osteoprotegerin1, 3. As a consequence of this disturbed 
equilibrium, approximately 80–90% of patients with MM develop osteolytic bone lesions, or soft 
spots that appear as ‘holes’ on a standard bone X-ray during the course of the disease4, 5. These 
lesions never heal spontaneously, weaken the bone, increase the risk of fractures, and are the 
primary cause of bone pain in patients with MM4, 5. During the course of the disease nearly all 
patients with MM are at risk of a broad range of bone complications, known as skeletal-related 
events (SREs)2, 6. These include: (1) pathologic fractures; (2) spinal cord compression; (3) surgery to 
bone; and (4) radiation to bone7. SREs are associated with a substantial decrease in the patients’ 
health-related quality of life, largely due to bone pain and forced immobility, as well as poor 
prognosis and increased risk of death associated with MM7–9.  
 
SREs are burdensome, not only for the patient, but also to the healthcare system. They lead to 
incrementally higher costs and healthcare resource use including significantly more hospitalizations, 
outpatient clinic visits and emergency department (ED) visits for patients with MM who have SREs 
versus those who do not10, 11. Furthermore, healthcare resource use also increases with SRE burden10, 
11. A retrospective analysis found that, overall, all-cause total costs were approximately $80,000 
(2016 US$) per patient per year (PPPY) higher for those with SREs than those without, and 
approximately $50,000 PPPY higher for those with multiple versus single SREs10. 
 
The prevention or reduction of bone complications is considered a major goal of supportive care for 
patients with MM12. International guidelines recommend initiating therapy to prevent SREs along 
with antimyeloma therapy for patients with active disease, even if osteolytic bone lesions are not 
apparent13, 14. Until recently, treatment options for the prevention of SREs in MM in the USA were 
limited to bisphosphonates, with zoledronic acid being the standard of care (4 mg intravenously [IV] 
every 3–4 weeks). Despite the predominance of zoledronic acid in this setting, it is not without 
limitations including safety warnings for renal toxicity15, risk of acute-phase reactions16, 17 and 
requiring intravenous administration15, all of which contribute to the healthcare resource burden in 
these patients18.  
 
Denosumab was recently approved in the USA for the prevention of SREs in patients with MM19. It is 
a fully human monoclonal antibody of the immunoglobulin G2 isotype that binds to and neutralizes 
RANKL, thereby inhibiting osteoclast activation and function19. In contrast to zoledronic acid, 
denosumab is not excreted via the kidneys and, consequently, can be used regardless of the 
patients’ renal function, with no renal monitoring or dose adjustments required15, 19. RANKL 
inhibition with denosumab is a novel approach to prevent SREs in patients with MM, as it exerts 
both potent antiresorptive activity and may have additional antitumor effects20. Denosumab is 
administered every 4 weeks (Q4W) as a subcutaneous injection (SC)19. Denosumab was approved in 
the USA and Europe for the prevention of SREs in patients with solid tumors in 2010; real-world data 
indicate that denosumab and zoledronic acid are the main agents used to prevent SREs in patients 
with solid tumors19, 21, 22.  
 
The safety and efficacy of denosumab, compared with zoledronic acid, for the prevention of SREs in 
patients with MM was recently evaluated in the 20090482 study (NCT01345019), one of the largest 
clinical trials in MM to date. In this phase 3, double-blind, multicenter study, 1718 patients with 
newly diagnosed MM were randomized 1:1 to receive denosumab (120 mg, SC, Q4W) or zoledronic 
acid (4 mg, intravenously [adjusted], Q4W)20. The study met its primary endpoint; denosumab was 
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 non-inferior to zoledronic acid in delaying time to first on-study SRE (hazard ratio [HR] = 0.98; 95% 
confidence interval [CI] = 0.85–1.14; p = 0.01). Owing to a high number of SREs (60%) during the first 
3 months of the study, a post hoc landmark analysis at 15 months was performed for time to first 
SRE. This showed that, compared with zoledronic acid, denosumab demonstrated better efficacy in 
delaying time to first SRE (HR = 0.66; 95% CI = 0.44–0.98; p = 0.039)20. Median progression-free 
survival (PFS), assessed as an exploratory endpoint, was 46.1 months with denosumab versus 35.4 
months with zoledronic acid (HR = 0.82; 95% CI = 0.68–0.99; descriptive p = 0.036), leading to an 
observed 10.7 month difference in median PFS between the two treatments20. Adverse events (AEs) 
in this phase 3 study reflected the known safety profile of each agent and were similar between 
treatment arms20. 
 
Integrated analysis of the data from three identically designed, randomized, double-blind, phase 3 
trials of patients with bone metastases and breast cancer, prostate cancer, other solid tumors or 
MM demonstrated that denosumab was superior to zoledronic acid in delaying the time to first 
SRE23, yet comparisons of the cost-effectiveness of denosumab and zoledronic acid have yielded 
variable conclusions24–30. This variability may have been caused by different perspectives of value. 
There is no single answer to the question of the value of an innovative drug. Traditionally, cost-
effectiveness analyses have focused on direct medical costs, such as drug acquisition costs, and their 
short-term budget impact31. More recently, additional factors such as the comprehensive clinical, 
humanistic and downstream economic benefits of drugs have been incorporated into economic 
models in order to provide a societal perspective on drug value31. In the current analysis, which 
aimed to assess the value of denosumab for the prevention of SREs in patients with MM, we have 
taken into account this societal perspective, which places the patient at the center of the analysis. 
We have also provided an analysis from the payer perspective.  
 
Given that denosumab has been shown to prevent or delay SREs, may extend PFS compared with 
zoledronic acid, and does not impact on renal function19, it was important to assess its economic 
value in patients with MM in the USA. The objective of the analysis was to estimate the incremental 
cost-effectiveness ratio (ICER) and the net monetary benefit (NMB) of denosumab versus zoledronic 
acid in patients with MM, from the perspectives of both society and payers. 
 
Methods 
The XGEVA® Global Economic Model (X-GEM) used for this analysis builds on the model published in 
Stopeck et al., 2012 that evaluated the cost-effectiveness of denosumab versus zoledronic acid for 
the prevention of SREs in patients with solid tumors in the USA28. The model incorporates outcomes 
of the 20090482 study20. 
 
Model design 
A partitioned survival model was constructed to assess the cost-effectiveness of denosumab versus 
zoledronic acid in patients with newly diagnosed MM by integrating the treatment and outcomes of 
a cohort of patients who are at risk of experiencing SREs. The model structure was the same for both 
treatment arms.  
 
Five health states were included, according to whether patients were on or off treatment with 
zoledronic acid or denosumab, had MM progression or not, or had died (Figure 1). Patients could 
transfer among health states every 4 weeks. The total time horizon was set to the patient’s 
remaining lifetime to capture all of the future health and economic outcomes expected from the 
alternatives compared32.  
 
Four types of SRE can occur – radiation to bone, surgery to bone, spinal cord compression and 
pathologic fracture – and each is associated with a different mean cost and impact on patient quality 
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 of life. To account for this, the model calculated the cost of a SRE based on the proportion of each 
type of SRE that occurred during the phase 3 study (Amgen data on file, 2017) (Table 1) and the cost 
of each SRE.  
 
Model population 
Patients newly diagnosed with MM and with at least one osteolytic lesion were included in the 
model. In order to reflect real-world practice, 10% of the model population was not able to receive 
zoledronic acid owing to pre-existing severe renal impairment33; the model assumed that these 
patients would be treated with denosumab. 
 
Model parameters 
Clinical input was obtained from the 20090482 study20 and included the SRE rates, the SRE 
distribution, treatment compliance rates, treatment discontinuation rates, PFS and overall survival 
(OS) rates and serious adverse event (SAE) rates. Treatment discontinuation rates, PFS and mortality 
rates were derived from probability curves fitted to trial data and extrapolated beyond the follow-up 
of the primary analysis. The follow-up for the primary analysis was up to 45 months; the median 
time on study was similar between the two arms (17.3 months for denosumab vs 17.6 months for 
zoledronic acid)20. Additionally, a real-world adjustment for SRE rates was applied to the clinical trial 
results. The rates of SREs, SAEs, PFS, OS and treatment discontinuation were modeled independently 
of each other.  
 
Skeletal-related event rates  
To calculate the trial-based annual SRE rate, using data from the 20090482 study20, the number of 
SREs experienced by patients in each arm was divided by the number of patient-years in the 
respective arm (Table 2).  
 
Consistent with other published cost-effectiveness analyses in this therapeutic area34, the model 
used constant rates for all SREs, the values of which depended on: (1) the specific treatment the 
patient was receiving to prevent SREs; and (2) whether the patient was on or off treatment for the 
prevention of SREs. Alternative SRE rate values, based on the results of a landmark analysis at 15 
months20, were also used. In this case, patients in each arm experienced differential rates before and 
15 months after the start of SRE preventive treatment (Table 3). 
 
The SRE rate for patients receiving no treatment (0.99 SRE/year) was estimated by dividing the SRE 
rate in the zoledronic acid arm by the rate ratio of SREs in patients with MM who were treated with 
zoledronic acid and patients with MM who did not receive treatment to prevent SREs; the rate ratio 
was taken from a managed care database study from the USA35. 
 
Skeletal-related event real-world adjustment  
Real-world studies have found that the SRE rate for zoledronic acid was higher than those reported 
from clinical trials36, 37. To account for this difference, a real-world adjustment relative rate ratio of 
2.84 was applied to the clinical trial results (i.e. the trial SRE rates were multiplied by the rate 
ratio)38. Although a real-world SRE adjustment factor lower than 2.84 has previously been reported 
for SREs in solid tumors36, the adoption of 2.84 in the base case for this analysis is consistent with 
the available (albeit limited) evidence of SRE rates in MM37, 38.  
 
Distribution of skeletal-related events 
The model considered the SRE distribution as observed in the 20090482 study (Amgen data on file, 
2017) without any further adjustment, as a proxy of real-world distribution of SREs (Table 1). 
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 Treatment compliance rates 
Treatment compliance was defined as the number of doses of zoledronic acid/denosumab received 
divided by the number of scheduled doses up to the end of investigational product administration 
for each patient. These data were derived from the 20090482 study20. The treatment compliance 
rate was 0.881 for denosumab and 0.854 for zoledronic acid. 
 
Treatment discontinuation rates 
Treatment discontinuation rates in the 20090482 study were similar between the denosumab and 
zoledronic acid arms20. The discontinuation of zoledronic acid and of denosumab was incorporated 
into the model based on treatment-specific data from the clinical trial with long-term extrapolation 
based on parametric fitting of the pooled individual data from the trial arms20. Treatment 
discontinuation rates were derived from the time-to-treatment-discontinuation probability 
distribution. Independent parametric fits using different distributions (exponential, Weibull, 
generalized gamma, log-logistic, log-normal) were performed. The Weibull and general gamma 
distributions were the two best fitting distributions according to the Akaike Information Criterion 
(AIC). The generalized gamma and Weibull distributions had very similar visual fit and long-term 
extrapolation with a mean time on treatment of 36.8 and 37.7 months, respectively. The generalized 
gamma probability distribution was deemed to be the most appropriate representation of 
discontinuation data and was, therefore, used in the base case. The same discontinuation rates were 
applied to both arms. After discontinuation, patients were assumed to experience the same SRE 
rates as patients who never received treatment to prevent SREs.   
 
Progression-free survival and overall survival rates 
PFS was defined as the time interval from the randomization date to the date of first overall disease 
progression assessed and recorded by the investigator, or death during treatment phase from any 
cause, whichever comes earlier. Data from study 20090482 showed an increasing separation 
between the denosumab and zoledronic acid PFS Kaplan–Meier curves from month 1 onwards20. 
Because the observed survival distributions for PFS were limited by the time of follow-up at primary 
analysis, it was necessary to extrapolate them beyond the currently available follow-up time to 
obtain unbiased estimates of the gains in life expectancy and QALYs in both treatment arms. This is a 
common approach to survival curves in modeling39. Extrapolation of PFS was performed by fitting 
parametric survival distributions to individual patient PFS data. The following exponential 
distributions were tested: exponential, Weibull, Gompertz, generalized gamma, log-logistic and log-
normal. The three best fitting distributions in terms of AIC were the Weibull, the log-logistic and the 
generalized gamma distributions. The three distributions were all associated with similar AICs and 
with relatively good visual fit to the trial data. Generalized gamma probability distributions (Figure 2) 
were deemed to be appropriate representations of PFS for both arms because they provided a good 
visual and statistical fit of PFS data; the log-logistic distribution provided an implausible long-term 
extrapolation of PFS (PFS curves crossed the OS curve after around 250 model cycles, at which time 
more than 10% of patients were still alive) and the median difference in PFS estimated by the 
generalized gamma distribution was closer to the results of study 20090482 than that estimated by 
the Weibull distribution. Furthermore, use of the generalized gamma distribution is consistent with 
the treatment discontinuation distribution, under the assumption of a constant relationship 
between time-to-treatment-discontinuation and treatment effect (which was also made for the SRE 
rates). Moreover, generalized gamma distributions of PFS have been used elsewhere to model PFS in 
patients with MM40, 41, and their projections appear to be clinically plausible. Rates were derived 
from the PFS probability distributions.   
 
Mortality rates were derived from the OS probability distribution, extrapolated by fitting survival 
data from the two pooled arms of the trial. In the 20090482 study, OS was similar for denosumab 
and zoledronic acid and, therefore, the model assumed the same mortality rate for both 
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 treatments20. Parametric survival models with different probability distributions were fitted to the 
data (namely exponential, Weibull, generalized gamma, log-logistic and log-normal distributions) 
and were used to inform the model. A correction was made using the US national life tables42 to 
ensure mortality rates predicted by the model would always be higher or equal to the general 
population mortality. The Weibull distribution was selected in the base case as it was the best fitting 
distribution based on the AIC and provided good visual fit. Although the exponential, generalized 
gamma and log-logistic distribution had similar statistical goodness of fit, the long-term 
extrapolations were not plausible, with exponential and log-logistic distributions predicting 
implausibly high long-term survival, while the generalized gamma distribution crossed the PFS 
extrapolation before 10 years. 
 
Serious adverse event rates 
To reflect clinically and economically important events, SAEs reported in the 20090482 study were 
used to derive SAE rates in the model. Constant rates of SAEs were used. A SAE was defined as any 
untoward medical occurrence that resulted in death, was life-threatening, required prolonged 
hospitalization, or resulted in significant disability/incapacity and which did not necessarily have to 
have a causal relationship with the administered treatment. Three SAEs were used to derive SAE 
rates included in the base case — hypocalcemia, osteonecrosis of the jaw (ONJ) and renal toxicity. 
SAE rates were calculated in a manner similar to the calculation of SRE rates by using the total 
number of patients experiencing each SAE and dividing it by the person-time on study over which 
patients were followed for SAEs. SAE rates were based on the integrated summary of safety from 
the 20090482 study20.  The rates of SAEs of interest for denosumab and zoledronic acid were as 
follows: hypocalcemia (0.9% vs 0.2%); positively adjudicated ONJ (0.7% vs 0.2%); and SAEs related to 
renal toxicity (2.7% vs 3.5%). 
 
Model utilities 
Utility decrements were a consequence of SREs, SAEs (such as ONJ, hypocalcemia and renal toxicity), 
mode of drug administration (subcutaneous injections vs intravenous infusions) and MM disease 
progression (Table 4).  
 
Skeletal-related event utility decrements 
The SRE utility values were derived from a sample of participants from the general population who 
participated in a utility study43, which was designed to establish the value that participants assigned 
to their quality of life, by hypothetically comparing varying life expectancies at different states of 
health. In this study, the utility decrements associated with the four types of SREs were assessed 
using eight health states – spinal cord compression (two health states: with and without paralysis), 
pathologic fracture (three health states: leg, rib and arm), radiation (two health states: administered 
in two appointments and administered daily for 2 weeks) and surgery performed to stabilize bone 
(one health state)43.  
 
Drug administration utility decrements 
A similar methodology was used for the assessment of the utility decrement associated with 
receiving a subcutaneous injection or intravenous infusion for SRE prevention (e.g. denosumab or 
zoledronic acid) in addition to antimyeloma chemotherapy43. The utility decrement for one 
subcutaneous injection compared with no injection was 0.0011, and that for one intravenous 
infusion compared with no infusion was 0.0021.  
 
Serious adverse events utility decrements 
The SAE utility decrements were based on analyses performed using a regression model by pooling 
data across solid tumor trials (Table 4)28.  
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 Multiple myeloma progression utility decrements 
MM progression was modeled by applying a 19.5% decrement to the baseline utility of patients with 
non-progressive disease, as previously done by van Agthoven et al., 200444, with a baseline utility of 
0.80 for patients with non-progressive disease (typically such patients were on, or had recently 
completed, first-line antimyeloma treatment).   
 
Costs  
The model inputs included direct medical costs for drug acquisition, drug administration, SAEs, SRE 
management (hospital, outpatient, long-term care and hospice, strong opioid, ED visits, physical 
therapy and skilled nursing facility), direct non-medical costs (for caregiver time and driving/parking 
time to attend medical appointments) and indirect costs (short-term disability and productivity loss). 
All of the above costs were included in the societal perspective analysis. The payer perspective did 
not include direct non-medical costs and indirect costs.  
 
Drug acquisition costs were based on average selling prices per dose (ASP; $1928 and $45 for 
denosumab and zoledronic acid, respectively) from the Centers for Medicare & Medicaid Services 
(Q3 2017)45. Wholesale drug acquisition costs per dose (WAC; $2155 and $922, respectively) in 2017 
were used for an alternative scenario analysis (Table 5). The doses given were: denosumab 120 mg 
subcutaneously every 4 weeks, zoledronic acid 4 mg intravenously every 4 weeks. Modifications to 
the zoledronic acid dose were performed according to the label. 
 
The costs of drug administration for subcutaneous injection and intravenous infusion (including an 
additional renal monitoring fee for each zoledronic acid administration) were taken from Stopeck et 
al., 201228, and adjusted for inflation to 2017 prices. The costs of SAEs (such as ONJ, hypocalcemia 
and renal toxicity) were also included46, 47 (Table 5). The monthly costs of antimyeloma treatments in 
first-, second- and third-line were based on WAC prices of regimens with at least 3% of market share 
(August 2017) weighted by their relative market shares and relative duration of use. The mean 
duration of each line of treatment was calculated as the mean duration of all the regimens with at 
least 3% of market share (August 2017) used for that line, weighted by their relative market shares. 
 
The inpatient and outpatient costs associated with managing SREs, accounting for the proportion of 
patients admitted for inpatient hospitalization or treated in outpatient facilities, are summarized in 
Table 5.  
 
The costs of SRE-related ED visits were calculated based on the study published by Nash et al., 
201611 evaluating the costs of treating patients with SREs versus treating those without SREs among 
patients with MM. Costs were reported as incremental cost per patient per month. Adjustments 
were made to account for the number of SREs during the follow-up period to estimate the cost per 
SRE. The SRE long-term care and hospice cost inputs were calculated based on a study by Jayasekara 
et al., 201448 and long-term care based on an internal analysis of the MarketScan claims database 
(Amgen data on file, 2017). The SRE physical therapy and devices costs were based on an internal 
analysis of the MarketScan claims database. Also in this case, costs were reported as incremental 
cost per patient per month and adjustments were made for the number of SREs per year. Other SRE-
related costs, associated with the use of skilled nursing facilities, strong opioid usage, caregiver 
burden and short-term disability and productivity loss were calculated based on multiple sources 
and are described in Table 5 (Amgen data on file, 2017)11, 48–52. All values were adjusted for inflation 
by multiplying the cost by the Medical Care consumer price index of March 2017. 
 
Cost-effectiveness analysis 
The cost-effectiveness of denosumab was calculated primarily in terms of the ICER by dividing the 
difference in total cost (∆C) between denosumab (Cdmab) and zoledronic acid (Czol) by the difference 
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 in health outcomes (∆E), measured in quality-adjusted life-years (QALYs) between denosumab 
(Edmab) and zoledronic acid (Ezol), therefore: ICER = ∆C / ∆E. To help define the economic value of 
denosumab, we applied a threshold for health gains called the willingness to pay (WTP) threshold. 
This reflects the maximum amount that society is willing to pay for one additional QALY gained53. A 
constant 3% annual discount rate, to account for time preferences in health gains, was used in the 
model for both health and costs. For this analysis, the WTP threshold was assumed to be $150,000, 
which is consistent with the value previously used by several stakeholders in the USA, and with 
World Health Organization (WHO) recommendations53 The value of denosumab was also estimated 
by the NMB, calculated as NMB = [(Edmab – Ezol) × WTP] − (Cdmab – Czol). Cost-effectiveness and NMB 
analyses were conducted both from societal and payer perspectives. For the societal analysis, based 
on demographic considerations, 35% of patients were assumed to be eligible for short-term 
disability and productivity loss. This was based on the proportion of patients who would be assumed 
to be employed full time while being treated. After first-line antimyeloma treatment with a mean of 
nine cycles, patients who do not have disease progression incur significantly lower costs than those 
with progressive disease due to the initiation of a new antimyeloma treatment. To account for the 
uncertainties and complexities of the rapidly evolving MM treatment landscape, conservatively, only 
50% of the potential savings associated with delaying initiation of second and subsequent lines of 
primary antimyeloma treatment were included in the calculations.  
 
We also conducted three scenario analyses to understand how changes in various inputs impacted 
on the cost-effectiveness of denosumab versus zoledronic acid. First, we changed the drug 
acquisition cost to use the WAC rather than the ASP. This was conducted to reflect the fact that the 
price for zoledronic acid varies by region (and may be higher than the ASP in some institutions) and 
to assess how much value is lost when comparing an innovative and a generic product. Second, we 
changed the efficacy of denosumab compared with zoledronic acid for the prevention of SREs by 
incorporating results from the pre-specified 15-month post hoc analysis of the 20090482 study. In 
the primary analysis, used in the base case, most on-study SREs occurred within the first 3 months. 
Owing to the short duration of patient exposure to treatment this may not have been long enough 
to detect treatment differences. The 15-month post hoc analysis was conducted 1 year after most 
SRE events occurred, at a time point when the biological effect of each drug is likely to be 
measurable. Finally, we changed the proportion of patients with severe renal impairment from 10% 
to 25%. This was performed because real-world data suggest that the 10% used in the base case is 
probably a conservative estimate of the real-world proportion of patients with MM and severe renal 
impairment54.  
 
The effect of parametric uncertainty on the ICER was evaluated via a one-way deterministic 
sensitivity analysis (this involved varying one parameter at a time to determine how model results 
were affected). The overall impact of the uncertainties affecting model parameters on the model 
output was evaluated using multivariate probabilistic sensitivity analyses (this involved varying 
multiple parameters simultaneously, the values of which were taken from their parameter-specific 
probability distributions, and then running the model 2000 times).  
 
Results 
Base case: societal and payer perspectives 
From a societal perspective, based on the ASPs, the use of denosumab instead of zoledronic acid 
resulted in an incremental cost of $26,329 (about 5% of the total lifetime SRE-related and primary 
antimyeloma treatment costs; Table 6) and an incremental benefit measured by QALYs of 0.2439, 
which translated into a cost of $107,939 per QALY gained (Table 7) and an NMB difference of 
$10,259 in favor of denosumab (Table 7; Figure 3a). When based on the WAC prices, the same 
analysis resulted in an ICER of $34,895 per QALY gained. 
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 From the payer perspective, based on the ASPs, the adoption of denosumab resulted in an 
incremental cost of $29,409 and an incremental benefit measured by a QALY of 0.2439, which 
translated into a cost of $120,569 per QALY gained and a NMB difference of $7179 in favor of 
denosumab (Table 8; Figure 3b). When based on the WAC prices, the same analysis resulted in an 
ICER of $47,525 per QALY gained.  
 
With ICERs below the WTP threshold of $150,000/QALY, denosumab was found to be cost-effective 
versus zoledronic acid, both from a societal and payer perspective, and regardless of whether drug 
acquisition costs were based on the ASP or WAC.  
 
Additional scenarios: landmark analysis, patients with renal impairment and real-world 
adjustment factor 
When the results of the landmark analysis20 were considered, the ICER from the societal perspective 
was $74,514 per QALY. If the proportion of patients with severe renal impairment was increased to 
25%, the ICER was $64,068 per QALY from a societal perspective. If the SRE rate was adjusted with a 
lower factor (2.1)36, and rates were based on the landmark analysis, the ICER was $102,585 per QALY 
from a societal perspective. 
 
Sensitivity analyses  
Univariate deterministic sensitivity analyses showed that the model results were relatively stable 
with respect to the values of key variables, and remained below the accepted threshold, with the 
exception of annual crude SRE rates and the post-progression utility decrement (see Figures 4 a and 
b). 
 
Probabilistic multivariate sensitivity analyses showed that, at a WTP threshold of $150,000, the 
probability of denosumab being cost-effective versus zoledronic acid was more than 63% from the 
societal perspective and 60% from the payer perspective.  
 
Discussion  
To our knowledge, this is the first study to assess the cost-effectiveness of denosumab versus 
zoledronic acid in patients with MM. This analysis quantified the economic value delivered by 
denosumab to society and payers using the best available clinical and economic evidence to capture 
a wide range of costs and benefits accrued over a patient lifetime. The cost-effectiveness of 
denosumab compared with zoledronic acid in patients with MM holds for a WTP threshold of 
$150,000 per QALY gained, which is considerably lower than the $300,000 WTP threshold frequently 
used for cost-effectiveness analysis of novel drugs55, 56. Denosumab also delivered a positive NMB to 
both society and payers. By quantifying the comparative value of treatments57, we hope that this 
analysis will support patients, clinicians and payers in making informed decisions on which agent to 
use for the prevention of SREs in patients with MM, which may ultimately help maximize patient 
outcomes. Given its substantial economic benefit, lack of renal toxicity, and expected impact on PFS, 
denosumab has the potential to provide value to patients, healthcare providers, payers and society. 
 
Although previous studies have assessed the cost-effectiveness of denosumab compared with 
zoledronic acid in patients with solid tumors24–30, it is not possible to directly compare the results of 
these previous analyses because of the different clinical settings. This is due to important differences 
in clinical outcomes reported from studies comparing the efficacy of these agents in solid tumors 
and in MM; denosumab has been shown to be superior compared with zoledronic acid in preventing 
SREs in patients with solid tumors23, whereas in MM denosumab has been shown to be non-inferior 
in preventing SREs and to extend PFS compared with zoledronic acid20.  
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 This economic evaluation has a number of strengths. In particular, the majority of clinical inputs 
were generated within a large, well-designed, double blind, randomized, controlled study comparing 
denosumab with zoledronic acid in patients with newly diagnosed MM. The model also accounts for 
direct non-medical costs and indirect costs that are usually neglected in other analyses (which 
typically focus solely on direct medical costs), and provides a more holistic view of the value of 
innovative drugs, such as denosumab. Moreover, the model bridges the gap between randomized 
controlled trials and real-world practice by accounting for important comorbidities (i.e. renal 
impairment), the route of drug administration, the extrapolation of key clinical outcomes beyond 
the clinical study follow-up, the impact on MM treatment and the costs and burden for patients and 
caregivers.  
 
There are, of course, several limitations and the results presented should be interpreted within the 
context of the data inputs and modeling assumptions adopted. For instance, the cost of SREs in 
patients with MM were assumed to be similar to the costs of SREs from solid tumors as cited in 
Stopeck et al., 201228. However, because these costs are associated specifically with treating SREs 
and not the primary tumor it is reasonable to assume that any cost differences between treating 
SREs in solid tumors and MM would be minor. Other costs of healthcare services were estimated 
from multiple published sources that were not necessarily derived from patients with MM and which 
varied by tumor type, patient population, country and other parameters. PFS, OS and time to 
discontinuation distributions were extrapolated beyond the follow-up of the primary analysis of the 
phase 3 study and it should be noted that long-term (lifetime) extrapolations are affected by 
uncertainty, as they depend on multiple factors (some of which are unknown) and on complex 
dynamics. Additionally, for simplicity, a medical consumer price index (CPI) for inflation was applied 
to all costs including non-medical costs. However, we anticipate that applying a non-medical CPI to 
non-medical costs would have minimal impact on the model. However, best modeling practices have 
been applied, and clinically and statistically motivated assumptions have been made whenever 
possible58. Finally, sensitivity analyses have been used to test the robustness of the results. 
 
Conclusions 
This analysis shows that denosumab is a cost-effective option for the prevention of SREs in patients 
with MM compared with the current standard of care, zoledronic acid. This is due to its combined 
impact on reducing SREs and the observed improvement of PFS compared with zoledronic acid, as 
well as its lack of impact on renal function. The available evidence points to the conclusion that 
denosumab would remain cost-effective under a variety of scenarios, providing value to patients, 
payers and society.  
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 Tables and Figures 
Table 1. SRE counts and distributions from the 20090482 study. 
SRE type 
Number of SREs 
pooled arms (N = 1718) 
SRE proportion (%) 
Pathologic fractures 1280 81.6 
Radiation to bone 174 11.1 
Surgery to bone 104 6.6 
Spinal cord compression 10 0.6 
Overall 1568 100.0 
 
SRE, skeletal-related event. 
Source: Amgen data on file, 2017. 
 
Table 2. SRE rates from the 20090482 study. 
Components of SRE rate calculation by 
treatment group 
Multiple myeloma  
(study 482) full analysis set 
Denosumab 
(N = 859) 
Zoledronic acid 
(N = 859) 
Number of SREs 764 804 
Person-years of follow-up 1285.6 1289.4 
Rate per person-year 0.59 0.62 
 
SRE, skeletal-related event. 
A real-world adjustment factor of 2.84 was applied to both treatment arms. 
Source: Amgen data on file, 2017. 
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 Table 3. SRE rates from the 20090482 study (differential rates before and 15 months after the start 
of SRE preventive treatment).  
  
Denosumab 
Zoledronic 
acid 
Treatment 
difference 120 mg Q4W 4 mg Q4W 
(N = 450) (N = 459) 
First 14 months 
Number of events 709 720   
Mean number of events per subject 0.83 0.84   
Rate ratio     0.99 
 (95% CI)     (0.87–1.13) 
 p value     0.91 
Month 15 and after 
Number of events 55 84   
Mean number of events per subject 0.12 0.18   
Rate ratio     0.71 
 (95% CI)     (0.48, 1.05) 
 p value     0.089 
 
CI, confidence interval; SRE, skeletal-related event. 
Source: Amgen data on file, 2017. 
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 Table 4. Utility decrements. 
 
SRE type Utility decrement Source 
Pathologic fracture 0.100 Matza et al., 201443 
Radiation to bone 0.120 Matza et al., 201443 
Surgery to bone 0.160 Matza et al., 201443 
Spinal cord compression 0.500 Matza et al., 201443 
Serious AE   
 ONJ 0.010 Stopeck et al., 201228 
 Hypocalcemia 0.008 Stopeck et al., 201228 
 Renal toxicity 0.015 Stopeck et al., 201228 
Mode of administration   
 SC injection 0.0011 Amgen data on file, 2017  
 IV infusion 0.0021 Amgen data on file, 2017 
MM disease   
 Non-progressed 0.800 van Agthoven et al., 200444 
 Progressed 0.644 van Agthoven et al., 200444 
 
AE, adverse event; IV, intravenous; MM, multiple myeloma; ONJ, osteonecrosis of the jaw; SC, 
subcutaneous injection; SRE, skeletal-related event.  
 
Table 5. Summary of all cost inputs. 
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 Direct costs (2017 adjusted costs) Cost (US$) Unit Source for cost 
calculations 
Drug costs    
 Drug cost – denosumab 1928/2155 Per dose ASP/WAC 
 Drug cost– zoledronic acid 45/922 Per dose ASP/WAC 
Administration costs   
 Administration fee – denosumaba 42.18 Per dose Stopeck et al., 201228 
 Administration fee – zoledronic acidb 184.17 Per dose Stopeck et al., 201228 
 Renal monitoring fee 25.52 Per dose Stopeck et al., 201228 
Costs by SRE   
Inpatient    
 Vertebral or non-vertebral fracture 9146 Per SRE episode Barlev et al., 201059 
 Radiation to bone 2228 Per SRE episode Barlev et al., 201059 
 Surgery to bone 38,557 Per SRE episode Barlev et al., 201059 
 Spinal cord compression 27,466 Per SRE episode Barlev et al., 201059 
Outpatient    
 Vertebral or non-vertebral fracture 1713 Per SRE episode Stopeck et al., 201228 
 Radiation to bone 10,003 Per SRE episode Stopeck et al., 201228 
 Surgery to bone 523 Per SRE episode Stopeck et al., 201228 
 Spinal cord compression 1611 Per SRE episode Stopeck et al., 201228 
Emergency department 536 Per SRE episode Nash Smyth et al., 
201611 
Long-term care and hospice 85 Per SRE episode LTC: Amgen 
MarketScan DoF 
Hospice (Amgen data 
on file, 2017), 
Jayasekera et al., 
201448 
Physical therapy and devices 11 Per SRE episode Amgen MarketScan 
DoF (Amgen data on 
file, 2017) 
Skilled nursing facility 1744 Per SRE episode Calculated on  
Jayasekera et al., 
201448 
Strong opioid use 26 Per SRE episode Calculated on  
von Moos et al., 
201650 
Delea et al., 200451 
SAEs    
 ONJ 660 Per SAE episode Xie et al., 201147, Bell 
et al., 201146 
 Hypocalcemia 166 Per SAE episode Xie et al., 201147, Bell 
et al., 201146 
 Renal toxicity 292 Per SAE episode Xie 201147, Bell 201146 
 
MM treatment costs (per month) 
   
 First line 18,272 Per month Based on WAC prices 
as of September 6, 
2017 
 Second line 18,256 Per month Based on WAC prices 
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 as of September 6, 
2017 
 Third line 18,367 Per month Based on WAC prices 
as of September 6, 
2017 
Direct non-medical and indirect costs  
(2017 adjusted costs) 
   
 SRE visit driving and parking time 58 Per SRE episode 2 hours driving for 
bone complication 
visit with a $5 parking 
fee. Average hourly 
rates used at a cost of 
$26.49 (BLS) 
 SRE caregiver burden 4835 Per SRE episode Gridelli et al., 200752 
 Short-term disability and productivity 
loss 
894 Per SRE episode Qian et al., 201549 
 
ASP, average selling price; BLS, United States Bureau of Labor Statistics; MM, multiple myeloma; 
ONJ, osteonecrosis of the jaw; SAE, serious adverse event; WAC, wholesale drug acquisition costs. 
 
Table 6. Costs by category (discounted). 
 
Costs by category (discounted), US$ 
Denosuma
b 
Zoledronic acid/no 
treatment 
Differenc
e 
Drug cost  63,805 1299 62,506 
Administration cost  1390 6063 –4673 
SAE cost  26 19 7 
Anti-MM treatment cost  127,322 147,471 –20,149 
SRE total direct medical costs 258,778 267,058 –8281 
SRE total direct non-medical and indirect 
costs 96,268 99,349 –3081 
Total 547,589 521,260 26,329 
 
MM, multiple myeloma; SAE, serious adverse event; SRE, skeletal-related event. 
 
Table 7. Comparator incremental cost-effectiveness ratio results from the societal perspective. 
  
Results (discounted) Denosumab Zoledronic acid/no treatment Difference 
Costs, US$ 547,589 521,260 26,329 
QALYs 3.400 3.156 0.2439 
Cost per QALY (ICER), US$ 107,939 
Net monetary benefit, US$ 10,259 
 
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year. 
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 Table 8. Comparator incremental cost-effectiveness ratio results from the payer perspective. 
 
Results (discounted) Denosumab Zoledronic acid/no treatment Difference 
Costs, US$ 451,320 421,911 29,409 
QALYs 3.400 3.156 0.2439 
Cost per QALY (ICER), US$ 120,569 
Net monetary benefit, US$ 7179 
 
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year. 
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 Figure 1. Depiction of model health states. 
 
1L, first line; 2L+, second line or later; MM, multiple myeloma; OFF SRE Prev Tx, patients not 
receiving treatment to prevent SREs; ON SRE Prev Tx, patients receiving treatment to prevent SREs; 
SRE, skeletal-related event; Tx, treatment. 
 
Figure 2. Progression-free survival parametric model (unrestricted generalized gamma distributions 
compared with Kaplan–Meier curves). 
 
KM, Kaplan–Meier; MM, multiple myeloma; PFS, progression-free survival. 
 
Figure 3. Net monetary benefit of denosumab versus zoledronic acid in patients with multiple 
myeloma from (a) the societal perspective and (b) the payer perspective. 
 
Societal perspective included SRE direct costs (hospital, outpatient, long-term care and hospice, 
strong opioid, emergency department visits, physical therapy and skilled nursing facility), QALY 
monetization and direct non-medical (driving and parking, caregiver) and indirect costs (short-term 
disability and productivity loss). Payer perspective included SRE direct costs (hospital, outpatient, 
long-term care and hospice, strong opioid, emergency department visits, physical therapy and skilled 
nursing facility) and QALY monetization. Assumed 50% MM treatment cost offsets and 35% patients 
eligible for short-term disability and productivity loss. Drug acquisition costs were based on average 
sales prices. 
 
MM, multiple myeloma; NMB, net monetary benefit; QALY, quality-adjusted life year; SAE, serious 
adverse event; SRE, skeletal-related event; ZA, zoledronic acid. 
 
Figure 4. One-way deterministic sensitivity analyses of key variables from (a) the societal perspective 
(b) the payer perspective. 
 
Ranges for parameters used were as follows: annual efficacy discount rate, 0.00–0.05; percentage of 
patients not eligible to receive zoledronic acid, 0.05–0.15; annual crude SRE rate denosumab, 0.55–
0.64; annual crude SRE rate zoledronic acid, 0.58–0.67; real world adjustment SRE rate, 2.01–4.01; 
SRE rate ratio for zoledronic acid versus no treatment, 0.42–0.82; zoledronic acid cost of 
administration, 189–231; denosumab number of cycles, 0.79–0.97; zoledronic acid number of cycles, 
0.77–0.94; post-progression utility decrement, 0.57–0.72; QALY decrement SC, 0.0009–0.0014; QALY 
decrement IV, 0.0017–0.0025; QALY decrement vertebral fracture, 0.05–0.15; QALY decrement non-
vertebral fracture, 0.05–0.15; MM second-line treatment duration, 7.66–9.36; percentage of 
potential savings in anti-MM treatment used in the cost-effectiveness analysis, 0.40–0.60; second-
line MM treatment monthly costs, 16,430–20,081; third-line MM treatment monthly costs, 16,530–
20,204.  
 
2L, second line; 3L, third line; CE, cost-effectiveness analysis; IV, intravenous; MM, multiple 
myeloma; RR, risk ratio; SC, subcutaneous injection; SRE, skeletal-related event; QALY, quality-
adjusted life-year. 
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